Chimeric adenovirus 5/35 vector containing the clade C HIV gag gene induces a cross-reactive immune response against HIV

Vaccine

Volumn 25, Issue 19, 2007, Pages 3809-3815

  Xin, Ke Qin ^a   Sekimoto, Yuka ^a   Takahashi, Toru ^a   Mizuguchi, Hiroyuki ^b   Ichino, Motohide ^a   Yoshida, Atsushi ^a   Okuda, Kenji ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

Animal model; HIV; Vaccine

Indexed keywords

ADENOVIRUS 5 35 VECTOR; ADENOVIRUS VECTOR; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ADENOVIRUS 35; ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHIMERA; CLADISTICS; CLINICAL STUDY; CONTROLLED STUDY; CROSS REACTION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LIVER TOXICITY; MALE; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRAL GENE THERAPY; VIRUS GENE; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS STRAIN; VIRUS TYPING;

ADENOVIRUSES, HUMAN; AIDS VACCINES; ANIMALS; CAPSID PROTEINS; CROSS REACTIONS; FEMALE; GENE PRODUCTS, GAG; GENES, GAG; GENETIC VECTORS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MACACA FASCICULARIS; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; VACCINIA VIRUS;

EID: 34247106238     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.01.117     Document Type: Article

References (46)

1. Lole K.S., Bollinger R.C., Paranjape R.S., Gadkari D., Kulkarni S.S., Novak N.G., et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 73 1 (1999) 152-160
2. Zhang L., Chen Z., Cao Y., Yu J., Li G., Yu W., et al. Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol 78 24 (2004) 13591-13599
3. van Harmelen J., Williamson C., Kim B., Morris L., Carr J., Karim S.S., et al. Characterization of full-length HIV type 1 subtype C sequences from South Africa. AIDS Res Hum Retroviruses 17 16 (2001) 1527-1531
4. Bukawa H., Fukushima J., Hamajima K., Kimura M., Tsuji T., Xin K.Q., et al. Antibody responses raised against a conformational V3 loop peptide of HIV-1. Microbiol Immunol 39 8 (1995) 607-614
5. Barouch D.H., Craiu A., Kuroda M.J., Schmitz J.E., Zheng X.X., Santra S., et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci USA 97 8 (2000) 4192-4197
6. Robinson H.L., Montefiori D.C., Johnson R.P., Manson K.H., Kalish M.L., Lifson J.D., et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 5 5 (1999) 526-534
7. Patterson L.J., Malkevitch N., Venzon D., Pinczewski J., Gomez-Roman V.R., Wang L., et al. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 78 5 (2004) 2212-2221
8. Schnell M.J., Foley H.D., Siler C.A., McGettigan J.P., Dietzschold B., and Pomerantz R.J. Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci USA 97 7 (2000) 3544-3549
9. Mandl C.W., Aberle J.H., Aberle S.W., Holzmann H., Allison S.L., and Heinz F.X. In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model. Nat Med 4 12 (1998) 1438-1440
10. Matano T., Kano M., Odawara T., Nakamura H., Takeda A., Mori K., et al. Induction of protective immunity against pathogenic simian immunodeficiency virus by a foreign receptor-dependent replication of an engineered avirulent virus. Vaccine 18 28 (2000) 3310-3318
11. Matano T., Kobayashi M., Igarashi H., Takeda A., Nakamura H., Kano M., et al. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med 199 12 (2004) 1709-1718
12. Caley I.J., Betts M.R., Davis N.L., Swanstrom R., Frelinger J.A., and Johnston R.E. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy. Vaccine 17 23-24 (1999) 3124-3135
13. Xin K.Q., Ooki T., Mizukami H., Hamajima K., Okudela K., Hashimoto K., et al. Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses. Hum Gene Ther 13 13 (2002) 1571-1581
14. Xin K.Q., Mizukami H., Urabe M., Toda Y., Shinoda K., Yoshida A., et al. The induction of robust immune responses against HIV is supported by the inherent tropism of AAV5 for DC. J Virol 80 24 (2006) 11899-11910
15. Aldovini A., and Young R.A. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature 351 6326 (1991) 479-482
16. Xin K.Q., Hoshino Y., Toda Y., Igimi S., Kojima Y., Jounai N., et al. Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. Blood 102 1 (2003) 223-228
17. Xiang Z.Q., Gao G.P., Reyes-Sandoval A., Li Y., Wilson J.M., and Ertl H.C. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol 77 20 (2003) 10780-10789
18. Wilson N.A., Reed J., Napoe G.S., Piaskowski S., Szymanski A., Furlott J., et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 80 12 (2006) 5875-5885
19. Sun Y., Schmitz J.E., Buzby A.P., Barker B.R., Rao S.S., Xu L., et al. Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge. J Virol (2006)
20. Santra S., Seaman M.S., Xu L., Barouch D.H., Lord C.I., Lifton M.A., et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 79 10 (2005) 6516-6522
21. Roberts D.M., Nanda A., Havenga M.J., Abbink P., Lynch D.M., Ewald B.A., et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441 7090 (2006) 239-243
22. Sakurai F., Mizuguchi H., Yamaguchi T., and Hayakawa T. Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. Mol Ther 8 5 (2003) 813-821
23. Shayakhmetov D.M., Papayannopoulou T., Stamatoyannopoulos G., and Lieber A. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol 74 6 (2000) 2567-2583
24. Roelvink P.W., Lizonova A., Lee J.G., Li Y., Bergelson J.M., Finberg R.W., et al. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 72 10 (1998) 7909-7915
25. Adams J.Y., Johnson M., Sato M., Berger F., Gambhir S.S., Carey M., et al. Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med 8 8 (2002) 891-897
26. Thomas C.E., Ehrhardt A., and Kay M.A. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4 5 (2003) 346-358
27. Gaggar A., Shayakhmetov D.M., and Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 9 11 (2003) 1408-1412
28. Xin K.Q., Jounai N., Someya K., Honma K., Mizuguchi H., Naganawa S., et al. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther 12 24 (2005) 1769-1777
29. Mizuguchi H., and Hayakawa T. Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene 285 1-2 (2002) 69-77
30. Seshidhar Reddy P., Ganesh S., Limbach M.P., Brann T., Pinkstaff A., Kaloss M., et al. Development of adenovirus serotype 35 as a gene transfer vector. Virology 311 2 (2003) 384-393
31. Havenga M.J., Lemckert A.A., Ophorst O.J., van Meijer M., Germeraad W.T., Grimbergen J., et al. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol 76 9 (2002) 4612-4620
32. Lieber A., He C.Y., Kirillova I., and Kay M.A. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol 70 12 (1996) 8944-8960
33. Amrein K.E., Takacs B., Stieger M., Molnos J., Flint N.A., and Burn P. Purification and characterization of recombinant human p50csk protein-tyrosine kinase from an Escherichia coli expression system overproducing the bacterial chaperones GroES and GroEL. Proc Natl Acad Sci USA 92 4 (1995) 1048-1052
34. Jounai N., Okuda K., Kojima Y., Toda Y., Hamajima K., Ohba K., et al. Contribution of the rev gene to the immunogenicity of DNA vaccines targeting the envelope glycoprotein of HIV. J Gene Med 5 7 (2003) 609-617
35. Barouch D.H., Santra S., Steenbeke T.D., Zheng X.X., Perry H.C., Davies M.E., et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol 161 4 (1998) 1875-1882
36. Raz E., Watanabe A., Baird S.M., Eisenberg R.A., Parr T.B., Lotz M., et al. Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc Natl Acad Sci USA 90 10 (1993) 4523-4527
37. Flores-Villanueva P.O., Zheng X.X., Strom T.B., and Stadecker M.J. Recombinant IL-10 and IL-10/Fc treatment down-regulate egg antigen-specific delayed hypersensitivity reactions and egg granuloma formation in schistosomiasis. J Immunol 156 9 (1996) 3315-3320
38. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 6869 (2002) 331-335
39. Sullivan N.J., Geisbert T.W., Geisbert J.B., Xu L., Yang Z.Y., Roederer M., et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424 6949 (2003) 681-684
40. Sullivan N.J., Sanchez A., Rollin P.E., Yang Z.Y., and Nabel G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408 6812 (2000) 605-609
41. Wadell G. Molecular epidemiology of human adenoviruses. Curr Top Microbiol Immunol 110 (1984) 191-220
42. Kostense S., Koudstaal W., Sprangers M., Weverling G.J., Penders G., Helmus N., et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. Aids 18 8 (2004) 1213-1216
43. Vogels R., Zuijdgeest D., van Rijnsoever R., Hartkoorn E., Damen I., de Bethune M.P., et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77 15 (2003) 8263-8271
44. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172 10 (2004) 6290-6297
45. Dhiman N., Jacobson R.M., and Poland G.A. Measles virus receptors: SLAM and CD46. Rev Med Virol 14 4 (2004) 217-229
46. Hsu E.C., Dorig R.E., Sarangi F., Marcil A., Iorio C., and Richardson C.D. Artificial mutations and natural variations in the CD46 molecules from human and monkey cells define regions important for measles virus binding. J Virol 71 8 (1997) 6144-6154